Microcap Ledger Rein Therapeutics, Inc. $RNTX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Austin, TX
- Fiscal year end
- December 31
- Shares outstanding
- 86,267,032 [10-Q 2026-08-14]
What the company doesAI summary of filing
Rein Therapeutics is a clinical-stage biopharmaceutical company developing therapies for orphan pulmonary and fibrosis indications. The company has two product candidates in clinical development: LTI-03, a peptide in Phase 2 trials for idiopathic pulmonary fibrosis, and LTI-01, a proenzyme that completed Phase 2a trials for loculated pleural effusion, though development of LTI-01 has been paused due to funding constraints. The company also has preclinical programs targeting cystic fibrosis and systemic fibrosis. Rein is pre-revenue and relies on third-party contract manufacturers; it has stated substantial doubt about its ability to continue as a going concern and requires additional capital beyond the second quarter of 2026 to sustain operations. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$12.21M | −$12.06M | $8.54M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $0.00 | −$49.90M | −$19.36M | $3.21M | [10-K 2026-03-26] |
| FY ended Dec 2024 | $0.00 | −$62.90M | −$22.29M | $12.87M | [10-K 2026-03-26] |
- Quarterly cash burn
- −$6.03M
- Cash runway Estimate
- ~4.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-24 | 28,039,032 | [10-K/A 2026-04-27] |
| 2025-03-27 | 21,992,387 | [10-K/A 2025-04-30] |
| 2025-05-14 | 22,153,736 | [10-Q 2025-05-15] |
| 2025-08-11 | 23,305,108 | [10-Q 2025-08-14] |
| 2025-11-10 | 26,286,382 | [10-Q 2025-11-14] |
| 2026-03-24 | 28,039,032 | [10-K 2026-03-26] |
| 2026-05-13 | 85,539,032 | [10-Q 2026-05-15] |
| 2026-08-12 | 86,267,032 | [10-Q 2026-08-14] |
- Shelf registration
- S-1 filed 2026-04-28; declared effective 2026-04-30 [S-1 2026-04-28]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-27. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-27] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-27 | Von Rickenbach Josef H | buy | 4,500 | $1.07 | [4 2026-05-28] |
| 2026-05-26 | Von Rickenbach Josef H | buy | 23,190 | $1.06 | [4 2026-05-28] |
| 2026-05-22 | Von Rickenbach Josef H | buy | 15,950 | $1.05 | [4 2026-05-28] |
| 2026-05-21 | Von Rickenbach Josef H | buy | 3,420 | $1.04 | [4 2026-05-28] |
| 2026-04-30 | Windsor James Brian | buy | 25,000 | $1.00 | [4 2026-05-13] |
| 2025-11-14 | Voss Capital, Lp | buy | 104,183 | $1.22 | [4 2025-11-18] |
| 2025-10-28 | Voss Capital, Lp | buy | 178,392 | $1.39 | [4 2025-10-28] |
| 2025-10-27 | Voss Capital, Lp | buy | 92,642 | $1.37 | [4 2025-10-28] |
| 2025-10-27 | Voss Capital, Lp | buy | 4,840 | $1.37 | [4 2025-10-28] |
| 2025-10-24 | Voss Capital, Lp | buy | 30,176 | $1.39 | [4 2025-10-28] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-04 | 8-K | Regulation FD disclosure |
| 2026-08-27 | 8-K | Listing notice or transfer |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-21 | 8-K | Shareholder vote results |
| 2026-07-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-08 | DEF 14A | Proxy statement |
| 2026-05-28 | PRE 14A | Proxy statement |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-08 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $RNTX
Email me when Rein Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.